Aspen Neuroscience Inc. (ASPE)
NASDAQ: ASPEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ASPE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $361.16M
- EPS (TTM)
- -$4.89
- Dividend yield
- None
- 52-week range
- 11.20 – 14.90
- Day range
- 12.17 – 13.19
- Volume / Avg
- 130.04K / 352.42K
- Beta
- —
- Shares outstanding
- 29.08M
52-week range
ASPE stock today
On Nov 20, ASPE ended the session at $12.42, adding $0.03 (0.24%), versus the S&P 500's 3.70% decline. Trading was light, with 130.04K shares changing hands, about 37% of the average daily volume. Shares are 16.6% below their 52-week high of $14.90, set on Oct 30, 2026 and 10.9% above the 52-week low of $11.20, in the middle of the past year's range.
Aspen Neuroscience has posted a net loss over the last twelve months (EPS of -$4.89), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Aspen Neuroscience
Company profileAspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases. The company's develops ANPD001, an investigational single-dose, autologous dopaminergic neuronal precursor cell (DANPC) therapy for Parkinson's disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Damien McDevitt Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 120
- IPO year
- 2026
- Website
- aspenneuroscience.com
Aspen Neuroscience peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PEPGPepGen Inc. | 3.78 | -3.82% | $356.31M | vs ASPE |
| PBYIPuma Biotechnology Inc | 7.05 | -0.98% | $364.47M | vs ASPE |
| PHATPhathom Pharmaceuticals Inc. | 4.66 | -8.27% | $378.82M | vs ASPE |
| CTNMContineum Therapeutics Inc. Class A | 8.68 | -3.98% | $340.83M | vs ASPE |
| IRDOpus Genetics Inc. | 3.99 | -2.21% | $385.65M | vs ASPE |
| MPLTMapLight Therapeutics Inc. | 5.94 | -7.48% | $330.12M | vs ASPE |
| AVTXAvalo Therapeutics Inc. | 6.76 | +0.15% | $390.88M | vs ASPE |
| INOInovio Pharmaceuticals Inc. | 1.76 | +2.92% | $329.66M | vs ASPE |
Indexes, lists and sector
Aspen Neuroscience stock FAQ
What is Aspen Neuroscience's stock price today?
ASPE last traded at $12.42 as of Nov 20, 4:00 PM EST, up 0.24% on the day. Prices are delayed at least 15 minutes.
Who is Aspen Neuroscience's CEO?
Dr. Damien McDevitt Ph.D. is the chief executive officer of Aspen Neuroscience Inc., which has about 120 employees.
What is the ASPE 52-week high?
The 52-week high for ASPE is $14.90 and the 52-week low is $11.20. The stock is currently 16.6% below its high.